Renaissance Technologies LLC Has $65,000 Stock Position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)

Renaissance Technologies LLC boosted its stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 63,910 shares of the company’s stock after buying an additional 26,310 shares during the period. Renaissance Technologies LLC owned approximately 0.24% of ImmunoPrecise Antibodies worth $65,000 as of its most recent filing with the SEC.

ImmunoPrecise Antibodies Price Performance

NASDAQ:IPA opened at $0.58 on Tuesday. ImmunoPrecise Antibodies Ltd. has a 1-year low of $0.50 and a 1-year high of $2.60. The company has a current ratio of 0.99, a quick ratio of 0.82 and a debt-to-equity ratio of 0.36. The firm has a fifty day simple moving average of $0.70 and a 200 day simple moving average of $0.97. The stock has a market capitalization of $15.17 million, a PE ratio of -1.41 and a beta of 0.09.

ImmunoPrecise Antibodies (NASDAQ:IPA) last released its earnings results on Monday, September 16th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.67% and a negative return on equity of 65.37%. The firm had revenue of $3.85 million during the quarter, compared to the consensus estimate of $4.96 million. On average, research analysts expect that ImmunoPrecise Antibodies Ltd. will post -0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IPA. Benchmark lowered their price objective on shares of ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating on the stock in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of ImmunoPrecise Antibodies in a report on Tuesday, September 17th.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.